Adam Cohen, MD, PhD is the founder and former CEO of the Center for Human Drug Research (CHDR) in Leiden, The Netherlands. Currently, Dr Cohen is Director of the CHDR’s Innovation Service (InnoS). CHDR (www.chdr.nl) is a prominent consultant to (bio)pharmaceutical companies, with special emphasis on early drug development and proof-of-concept studies in patients. Dr Cohen is emeritus Professor of Clinical Pharmacology at Leiden University Medical Center (LUMC). He authored are broad range of publications on a wide range of clinical pharmacological subjects. He is Editor-in-chief of the British Journal of Clinical Pharmacology.
Rune Frants, PhD is emeritus Professor of Medical Genetics at Leiden University Medical Center, The Netherlands. Dr Frants has worked on a plethora of genetically determined disorders, including neuromuscular diseases, in particular FSHD; neurogenetics, in particular migraine and other forms of headache; lung emphysema; gastric cancer; skin cancer; and cardiovascular disease. He has mentored some 30 PhD students and authored some 400 peer-reviewed articles. Currently, Dr Frants consults with the Leiden Center for Translational Neuroscience. He is also a member of the Scientific Advisory Board of the US FSH Society.
George Padberg, MD, PhD is emeritus Professor of Neurology and former Head of the Department of Neurology at Radboud University Medical Center in Nijmegen, The Netherlands. His 1982 PhD thesis is still regarded as a landmark study of FSHD. He is an author of about 180 publications, mainly on FSHD, but also on Möbius syndrome, spinal muscular atrophy, limb girdle muscular dystrophy and forms of cancer. Dr Padberg serves on various scientific boards, including the Scientific Advisory Board and the STAR committee of the FSH Society in the USA; he is advisor of FSH Europe and is the former Scientific Director of the European Neuromuscular Center (ENMC). He also sits on the Board of the Dutch FSHD Foundation and is active as a medical advisor in the Netherlands Association of Neuromuscular Diseases. In 2008, he was named Officer in the Order of Orange Nassau.”
Prof. Dr. Gerd Schnorrenberg has extensive experience in pharmaceutical research and development in several therapeutic areas. He recently retired from Boehringer Ingelheim Pharma GmbH & Co KG, where he was Head of Research, Germany, and member of the International Research Committee overseeing all research activities. In the course of a career that spanned 36 years, he made many contributions to Boehringer Ingelheim’s research and development pipeline and drug approvals across a variety of disease domains. Gerd lectured in medicinal chemistry at Johannes Gutenberg University (Mainz, Germany) and received an honorary professorship from the German federal State of Rheinland-Pfalz. He received his PhD from the University of Bonn and spent a sabbatical at the University of California in San Diego and at Massachusetts Institute of Technology.